U.S. Markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
22.47-2.32 (-9.36%)
At close: 4:00PM EDT

22.50 0.03 (0.13%)
After hours: 5:56PM EDT

People also watch
  • Form S-8 filed on June 21st for 3,600,000 shares of dilution for Incentive Compensation.
    Insiders are filling their pockets while the going is good.
  • Don't shoot the messenger, but it feels like a secondary is about to hit! Buy it!!
  • Insiders Cashing Out:
    Jacobsen - on 6/13 to 6/15, exercised options at $9.37 and then DUMPED 24,000 shares at $19.95 to $22.45
  • secondary coming very soon at substaltial discount if you have profit i would take it or short the he'll out of it till It gets to secondary price I'm guessing 18
  • Just bought some and this is just algorithms looking at options and letting the Big Boys grab shares from weak hands! Guess GD sold his and went all in on RAD! Now that would be too speculative for me and way too much risk! Amazed how the naive investor lets their shares get sold because they are told to do a stop loss! Too bad the SEC doesn't have the cahones to go after the ones that do this but glad I added and when ahusOms721 gets approved I will have even more to be happy about!
  • Junk
  • I told you this was a great short, last week.
  • Will repeat again. Everything under $1B market cap is dirt cheap in long run considering Omidria is gonna fund the whole pipeline soon and "sky is the limit" pipeline. I'd rather put all money in OMER than in any other overhyped cancer targeting pharma with ridiculous $2-3B market cap, zero appoved products and no revenue.
  • Buy under $25, average down if it goes lower. Long term you will be rewarded
  • http://bangaloreweekly.com/omeros-corporation-omer-stock-rating-reaffirmed-by-wbb-securities-324586.html

    The Omeros Corporation (OMER) Stock Rating Reaffirmed by WBB Securities - BangaloreWeekly
    Several other equities analysts have also weighed in on OMER. Wedbush restated an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a report on Tuesday, February 21st. Maxim Group restated a “buy” rating on shares o
  • Maybe 18?
  • all biotecs getting a shellacking today
  • Picked some up at 22.35, glad I waited la few trading days.
  • Circuit breakers remain in effect for tomorrow.
  • No buyer's stepping in yet.
  • there is no approved drug for the treatment of IgAN and OMS721 is the only candidate in this indication that has been granted this designation.
  • to all longs... put limit sell order on your shrs at $100 in thats way your broker can not lend your shrs to shorts seller.. need all longs to do that to have some effects.
  • Circuit breakers have been triggered.
  • Although Omeros Corporation's market cap has more than doubled this year to about $1.09 billion, there's plenty of fuel in the tank. If Omidria and OMS721 continue on their path to blockbuster status, the stock could double yet again over the next few years.
  • Let's see if we can stop the bleeding tomorrow.